(Q46856649)

English

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

scientific article published on 10 December 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

1 reference

based on heuristic

inferred from title

author name string

Benekli M

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Smiley SL

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Younis T

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Czuczman MS

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Hernandez-Ilizaliturri F

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Bambach B

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Battiwalla M

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Padmanabhan S

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

McCarthy PL Jr

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Hahn T

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

language of work or name

0 references

publication date

10 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

41

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

613-619

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

Approach to Hodgkin's lymphoma in the new millennium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

BEAM autografting in lymphoma--experience at one centre.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

21 January 2018

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive disease after ABMT for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American M

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705951

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705951

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18071290

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46856649&oldid=2208182398"